| 1.38 -0.13 (-8.61%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.04 | 1-year : | 3.97 |
| Resists | First : | 2.6 | Second : | 3.4 |
| Pivot price | 1.37 | |||
| Supports | First : | 1.33 | Second : | 1.1 |
| MAs | MA(5) : | 1.37 | MA(20) : | 1.37 |
| MA(100) : | 1.93  |
MA(250) : | 1.96 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.4 | D(3) : | 2.4 |
| RSI | RSI(14): 26.6 | |||
| 52-week | High : | 3.88 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MEUSW ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.
Wed, 07 Feb 2024
23andMe Holding Co. (ME) Q3 2024 Earnings Call Transcript - Seeking Alpha
Wed, 16 Jun 2021
23andMe Successfully Closes its Business Combination with VG Acquisition Corp. - GlobeNewswire
Wed, 16 Jun 2021
23andMe and Virgin Group's VG Acquisition Corp. successfully close business combination | Virgin - Virgin
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|